{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T09:51:59Z","timestamp":1793267519751,"version":"4.5.0"},"reference-count":239,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1053\/j.seminoncol.2009.07.009","type":"journal-article","created":{"date-parts":[[2009,10,15]],"date-time":"2009-10-15T04:17:52Z","timestamp":1255580272000},"page":"381-418","source":"Crossref","is-referenced-by-count":71,"title":["Lymphoma in Adolescents and Young Adults"],"prefix":"10.1053","volume":"36","author":[{"given":"Samantha M.","family":"Jaglowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Linden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda M.","family":"Termuhlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2009.07.009_bib1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer Statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib2","series-title":"Lymphomas and Reticuloendothelial Neoplasms. ICCCII. National Cancer Institute SEER Pediatric Monograph","first-page":"35","author":"Percy","year":"2009"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib3","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/1097-0142(19841001)54:7<1435::AID-CNCR2820540734>3.0.CO;2-O","article-title":"Non-Hodgkin's lymphomas","volume":"54","author":"Percy","year":"1984","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib4","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cppeds.2005.02.001","article-title":"The adolescent and young adult gap in cancer care and outcome","volume":"35","author":"Bleyer","year":"2005","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib5","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/cncr.10403","article-title":"Changing incidence of non-Hodgkin lymphomas in the United States","volume":"94","author":"Clarke","year":"2002","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib6","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"The Non-Hodgkin's Lymphoma Classification Project","volume":"89","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib7","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0140-6736(88)90367-4","article-title":"Updated Kiel classification for lymphomas","volume":"1","author":"Stansfeld","year":"1988","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/1097-0142(197410)34:8+<1488::AID-CNCR2820340822>3.0.CO;2-C","article-title":"Immunologic characterization of human malignant lymphomas","volume":"34","author":"Lukes","year":"1974","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib9","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib10","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","article-title":"World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997","volume":"17","author":"Harris","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib11","series-title":"Who Classification of Tumours of Haematopoietic and Lymphoid Tissues. Vol 4","author":"Harris","year":"2008"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/cncr.11903","article-title":"Fine-needle cytology and flow cytometry immunophenotyping and subclassification of non-Hodgkin lymphoma: a critical review of 307 cases with technical suggestions","volume":"102","author":"Zeppa","year":"2004","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib13","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/modpathol.3880336","article-title":"Fine-needle aspiration biopsy in the diagnosis and classification of primary and recurrent lymphoma: a retrospective analysis of the utility of cytomorphology and flow cytometry","volume":"14","author":"Dong","year":"2001","journal-title":"Mod Pathol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib14","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1200\/JCO.2004.02.104","article-title":"Utility of fine-needle aspiration as a diagnostic technique in lymphoma","volume":"22","author":"Hehn","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000326095","article-title":"Diagnosis of lymphoma by image-guided needle biopsies: fine needle aspiration biopsy, core biopsy or both?","volume":"49","author":"Ravinsky","year":"2005","journal-title":"Acta Cytol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib16","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1001\/jama.1984.03350100051031","article-title":"When to perform biopsies of enlarged peripheral lymph nodes in young patients","volume":"252","author":"Slap","year":"1984","journal-title":"JAMA"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib17","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1200\/JCO.1983.1.5.326","article-title":"End results of treating children with localized non-Hodgkin's lymphomas with a combined modality approach of lessened intensity","volume":"1","author":"Murphy","year":"1983","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib18","first-page":"1860","article-title":"Report of the Committee on Hodgkin's Disease Staging Classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib19","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib20","first-page":"332","article-title":"Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults","volume":"7","author":"Murphy","year":"1980","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib21","series-title":"Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000","article-title":"Lymphomas and reticuloendothelial neoplasms","author":"O\u2019Leary","year":"2006"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib22","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJM199605093341906","article-title":"Non-Hodgkin's lymphoma in childhood","volume":"334","author":"Sandlund","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib23","series-title":"Diffuse large B-cell lymphoma. Vol 4","author":"Stein","year":"2008"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2141.2005.05735.x","article-title":"The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence","volume":"131","author":"Burkhardt","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib25","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1158\/1055-9965.EPI-06-1070","article-title":"Altered immunity as a risk factor for non-Hodgkin lymphoma","volume":"16","author":"Grulich","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib26","series-title":"Robbins and Cotran pathologic basis of disease","first-page":"598","article-title":"Neoplastic Proliferations of white cells","author":"Kumar","year":"2005"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib27","first-page":"1137","article-title":"Use of the Working Formulation for non-Hodgkin's lymphoma in epidemiologic studies: agreement between reported diagnoses and a panel of experienced pathologists","volume":"78","author":"Dick","year":"1987","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/1097-0142(19850101)55:1<91::AID-CNCR2820550115>3.0.CO;2-K","article-title":"Reproducibility of major classification systems","volume":"55","year":"1985","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib29","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1080\/10428190801911662","article-title":"Immune surveillance of EBV-infected B cells and the development of non-Hodgkin lymphomas in immunocompromised patients","volume":"49","author":"Pietersma","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib30","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1182\/blood.V96.12.3681","article-title":"CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features","volume":"96","author":"Stein","year":"2000","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib31","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib32","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib33","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1182\/blood.V98.4.945","article-title":"Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma","volume":"98","author":"Lossos","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib34","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/path.1924","article-title":"Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma","volume":"208","author":"Muris","year":"2006","journal-title":"J Pathol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0002-9440(10)63284-1","article-title":"BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma","volume":"165","author":"Iqbal","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib36","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2005-10-4213","article-title":"Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) multicenter trial","volume":"107","author":"Oschlies","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cancergencyto.2004.01.008","article-title":"Cytogenetics and fluorescence in situ hybridization studies of diffuse large B-cell lymphoma in children and young adults","volume":"153","author":"Dave","year":"2004","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib38","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/pbc.21619","article-title":"Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-myc protein expression, and a high incidence of germinal center subtype: report of the French-American-British (FAB) international study group","volume":"51","author":"Miles","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib39","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/leu.2008.312","article-title":"Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB\/LMB 96 international study","volume":"23","author":"Poirel","year":"2009","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib40","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib41","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bbmt.2007.11.013","article-title":"Salvage therapy for relapsed\/refractory diffuse large B cell lymphoma","volume":"14","author":"Seshadri","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib42","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM198706113162401","article-title":"High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma","volume":"316","author":"Philip","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib43","first-page":"3294","article-title":"Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster group trial NHL-BFM 90","volume":"94","author":"Reiter","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib44","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V97.11.3370","article-title":"The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia","volume":"97","author":"Patte","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib45","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/10428190601078944","article-title":"CODOX-M\/IVAC (NCI 89-C-41) in children and adolescents with Burkitt's leukemia\/lymphoma and large B-cell lymphomas: a 15-year monocentric experience","volume":"48","author":"Moleti","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib46","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/blood-2006-07-036673","article-title":"Results of the randomized international FAB\/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients","volume":"109","author":"Patte","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib47","series-title":"Mature B-cell neoplasms","first-page":"2130","article-title":"cancer: principles and practice of oncology","author":"Devita","year":"2008"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib48","first-page":"735","article-title":"Discordant expression of immunoglobulin and its associated molecule mb-1\/CD79a is frequently found in mediastinal large B cell lymphomas","volume":"146","author":"Kanavaros","year":"1995","journal-title":"Am J Pathol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib49","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2003-06-1841","article-title":"The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma","volume":"102","author":"Savage","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib50","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/1097-0142(19830515)51:10<1777::AID-CNCR2820511003>3.0.CO;2-E","article-title":"The discovery of Burkitt's lymphoma","volume":"51","author":"Burkitt","year":"1983","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib51","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0140-6736(64)91524-7","article-title":"Virus particles in cultured lymphoblasts from Burkitt's lymphoma","volume":"1","author":"Epstein","year":"1964","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib52","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00043426-199122000-00019","article-title":"African Burkitt's lymphoma","volume":"13","author":"Magrath","year":"1991","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-004-0939-7","article-title":"Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology","volume":"84","author":"Muller","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib54","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1200\/JCO.2000.18.21.3707","article-title":"Molecular biology of Burkitt's lymphoma","volume":"18","author":"Hecht","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib55","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1182\/blood-2004-02-0405","article-title":"Adult Burkitt leukemia and lymphoma","volume":"104","author":"Blum","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib56","series-title":"E-pub ahead of print","article-title":"Screening for residual disease in pediatric Burkitt lymphoma using consensus primer pools","author":"Agsalda","year":"2009"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib57","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/1097-0142(19950101)75:1+<370::AID-CNCR2820751319>3.0.CO;2-Q","article-title":"Non-Hodgkin's lymphoma","volume":"75","author":"Greiner","year":"1995","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib58","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2","article-title":"summary and description of a working formulation for clinical usage","volume":"49","year":"1982","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib59","series-title":"Burkitt lymphoma. Vol 4","author":"Leoncini","year":"2008"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib60","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/jcp.56.3.188","article-title":"Burkitt's lymphoma: new insights into molecular pathogenesis","volume":"56","author":"Bellan","year":"2003","journal-title":"J Clin Pathol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib61","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1046\/j.1365-2141.2003.04134.x","article-title":"Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group experience","volume":"120","author":"Cairo","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib62","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0031-3955(16)33277-1","article-title":"Non-Hodgkin's lymphoma in children","volume":"23","author":"Wollner","year":"1976","journal-title":"Pediatr Clin North Am"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib63","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1002\/1097-0142(197912)44:6<1990::AID-CNCR2820440605>3.0.CO;2-9","article-title":"Non-Hodgkin's lymphoma in children: a progress report on the original patients treated with the LSA2-L2 protocol","volume":"44","author":"Wollner","year":"1979","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib64","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1200\/JCO.1986.4.8.1219","article-title":"Improved survival rate in children with stage III and IV B cell non-Hodgkin's lymphoma and leukemia using multi-agent chemotherapy: results of a study of 114 children from the French Pediatric Oncology Society","volume":"4","author":"Patte","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib65","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1200\/JCO.1991.9.1.123","article-title":"High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children","volume":"9","author":"Patte","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib66","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/1097-0142(19850115)55:2<323::AID-CNCR2820550204>3.0.CO;2-9","article-title":"Pediatric Oncology Group experience with modified LSA2-L2 therapy in 107 children with non-Hodgkin's lymphoma (Burkitt's lymphoma excluded)","volume":"55","author":"Sullivan","year":"1985","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib67","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/JCO.1991.9.1.133","article-title":"HiC-COM: a 2-month intensive chemotherapy regimen for children with stage III and IV Burkitt's lymphoma and B-cell acute lymphoblastic leukemia","volume":"9","author":"Schwenn","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib68","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1200\/JCO.2002.08.088","article-title":"Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children","volume":"20","author":"Spreafico","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib69","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1182\/blood.V63.5.1102.1102","article-title":"An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults","volume":"63","author":"Magrath","year":"1984","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib70","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.1996.14.4.1252","article-title":"Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a Pediatric Oncology Group study","volume":"14","author":"Bowman","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib71","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2006-07-036665","article-title":"Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents","volume":"109","author":"Cairo","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib72","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/annonc\/mdf253","article-title":"An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study","volume":"13","author":"Mead","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib73","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1200\/JCO.1986.4.6.847","article-title":"Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types)","volume":"4","author":"Bernstein","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib74","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/8.suppl_1.S77","article-title":"Eighty-one percent event-free survival in advanced Burkitt's lymphoma\/leukemia: no differences in outcome between pediatric and adult patients treated with the same intensive pediatric protocol","volume":"8","author":"Todeschini","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib75","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/JCO.1996.14.3.925","article-title":"Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen","volume":"14","author":"Magrath","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib76","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1200\/JCO.1999.17.8.2461","article-title":"Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia","volume":"17","author":"Thomas","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib77","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib78","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.V99.6.1959","article-title":"Clinicopathologic analysis of follicular lymphoma occurring in children","volume":"99","author":"Lorsbach","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib79","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1002\/1097-0142(197912)44:6<2218::AID-CNCR2820440634>3.0.CO;2-D","article-title":"Follicular (nodular) lymphoma in childhood: a rare clinical-pathological entity. Report of eight cases from four cancer centers","volume":"44","author":"Frizzera","year":"1979","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib80","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/10428190701742472","article-title":"Frequency of BCL2 and BCL6 translocations in follicular lymphoma: relation with histological and clinical features","volume":"49","author":"Diaz-Alderete","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib81","series-title":"Follicular lymphoma","first-page":"220","author":"Harris","year":"2008"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib82","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1182\/blood.V99.10.3806","article-title":"Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3","volume":"99","author":"Ott","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib83","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1097\/01.pas.0000182405.65041.8b","article-title":"Bone marrow biopsy involvement by non-Hodgkin's lymphoma: frequency of lymphoma types, patterns, blood involvement, and discordance with other sites in 450 specimens","volume":"29","author":"Arber","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib84","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1182\/blood.V90.8.2863","article-title":"Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy","volume":"90","author":"Jennings","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib85","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/asheducation-2004.1.203","article-title":"Low-grade lymphoma","author":"Winter","year":"2004","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib86","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0002-9440(10)64897-3","article-title":"Detection of BCL2 rearrangements in follicular lymphoma","volume":"160","author":"Aster","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib87","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.1158\/1078-0432.CCR-08-0752","article-title":"Clonal evolution in t(14;18)-positive follicular lymphoma, evidence for multiple common pathways, and frequent parallel clonal evolution","volume":"14","author":"d'Amore","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib88","doi-asserted-by":"crossref","first-page":"6358","DOI":"10.1200\/JCO.2005.26.856","article-title":"Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors","volume":"23","author":"de Jong","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib89","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/blood.V88.2.386.bloodjournal882386","article-title":"Molecular thanatopsis: a discourse on the BCL2 family and cell death","volume":"88","author":"Yang","year":"1996","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib90","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1182\/blood.V93.9.3081","article-title":"Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma","volume":"93","author":"Lopez-Guillermo","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib91","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood.V91.8.2955.2955_2955_2960","article-title":"The clinical significance of molecular response in indolent follicular lymphomas","volume":"91","author":"Lopez-Guillermo","year":"1998","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib92","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1074-7613(00)00020-0","article-title":"BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control","volume":"13","author":"Shaffer","year":"2000","journal-title":"Immunity"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib93","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1038\/sj.leu.2402707","article-title":"Follicular lymphoma without t(14;18) and with BCL-6 rearrangement: a lymphoma subtype with distinct pathological, molecular and clinical characteristics","volume":"16","author":"Jardin","year":"2002","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib94","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib95","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.1998.16.7.2332","article-title":"Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 trial","volume":"16","author":"Solal-Celigny","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib96","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/jcp.55.9.684","article-title":"Primary follicular lymphoma of the testis in childhood: an entity with peculiar clinical and molecular characteristics","volume":"55","author":"Pileri","year":"2002","journal-title":"J Clin Pathol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib97","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: first report of the national LymphoCare study","volume":"27","author":"Friedberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib98","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib99","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib100","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib101","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib102","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/jnci\/djn478","article-title":"Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials","volume":"101","author":"Vidal","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib103","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma\u2014a randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib104","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib105","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib106","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1200\/JCO.2006.09.8327","article-title":"Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up","volume":"25","author":"Rohatiner","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib107","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1182\/blood.V88.7.2780.bloodjournal8872780","article-title":"High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission","volume":"88","author":"Freedman","year":"1996","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib108","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2008-05-160200","article-title":"High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years","volume":"113","author":"Gyan","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib109","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib110","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1093\/annonc\/mdn691","article-title":"Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up","volume":"20","author":"Kornacker","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib111","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma","volume":"102","author":"van Besien","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib112","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/annonc\/mdg200","article-title":"Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma","volume":"14","author":"Hosing","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib113","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2141.2004.05194.x","article-title":"Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation","volume":"127","author":"Toze","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib114","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib115","series-title":"T Lymphoblastic leukaemia\/lymphoma. Vol 4","author":"Borowitz","year":"2008"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib116","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1097\/00000478-200011000-00003","article-title":"Precursor B-cell lymphoblastic lymphoma: a predominantly extranodal tumor with low propensity for leukemic involvement","volume":"24","author":"Lin","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib117","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/sj.leu.2404302","article-title":"Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast","volume":"20","author":"Graux","year":"2006","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib118","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0889-8588(05)70200-8","article-title":"Lymphoblastic lymphoma","volume":"15","author":"Thomas","year":"2001","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib119","article-title":"Advances in the diagnostic approach to childhood lymphoblastic malignant neoplasms","volume":"122","author":"Reddy","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib120","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1182\/blood.V66.5.1110.1110","article-title":"A novel treatment of childhood lymphoblastic non-Hodgkin's lymphoma: early and intermittent use of teniposide plus cytarabine","volume":"66","author":"Dahl","year":"1985","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib121","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1200\/JCO.1986.4.11.1628","article-title":"Treatment of lymphoblastic lymphoma in adults","volume":"4","author":"Coleman","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib122","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1056\/NEJM198303103081003","article-title":"Childhood non-Hodgkin's lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2)","volume":"308","author":"Anderson","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib123","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.1983.1.9.537","article-title":"Long-term results of the APO protocol (vincristine, doxorubicin [Adriamycin], and prednisone) for treatment of mediastinal lymphoblastic lymphoma","volume":"1","author":"Weinstein","year":"1983","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib124","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.1988.6.1.26","article-title":"Lymphoblastic lymphoma in children\u2014a randomized trial comparing LSA2-L2 with the A-COP+ therapeutic regimen: a Pediatric Oncology Group study","volume":"6","author":"Anderson","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib125","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1200\/JCO.1992.10.7.1078","article-title":"Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients","volume":"10","author":"Morel","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib126","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1200\/JCO.1993.11.6.1024","article-title":"Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Childrens Cancer Group","volume":"11","author":"Anderson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib127","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1200\/JCO.1995.13.6.1368","article-title":"Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study","volume":"13","author":"Tubergen","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib128","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/cncr.11615","article-title":"Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center","volume":"98","author":"Mora","year":"2003","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib129","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1182\/blood-2003-12-4428","article-title":"Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib130","first-page":"416","article-title":"Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report","volume":"95","author":"Reiter","year":"2000","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib131","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.2005.02.2707","article-title":"Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma","volume":"24","author":"Burkhardt","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib132","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1200\/JCO.1998.16.3.920","article-title":"Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group","volume":"16","author":"Nachman","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib133","doi-asserted-by":"crossref","first-page":"3610a","DOI":"10.1182\/blood.V112.11.3610.3610","article-title":"High-dose methotrexate and early intensification of therapy do not improve 3 year EFS in children and adolescents with disseminated lymphoblastic lymphoma. Results of the randomized arms of COG A5971 [abstract]","volume":"112","author":"Abromowitch","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib134","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1182\/blood-2002-01-0110","article-title":"Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia","volume":"99","author":"Hoelzer","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib135","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3109\/10428199609054867","article-title":"Adult lymphoblastic lymphoma: clinical features and prognostic factors in 53 patients","volume":"23","author":"Zinzani","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib136","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1200\/JCO.1995.13.2.359","article-title":"Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage\u2014a report of the Berlin-Frankfurt-Munster group","volume":"13","author":"Reiter","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib137","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/blood.V66.4.848.bloodjournal664848","article-title":"The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells","volume":"66","author":"Stein","year":"1985","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib138","first-page":"2697","article-title":"ALK+ lymphoma: clinico-pathological findings and outcome","volume":"93","author":"Falini","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib139","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","first-page":"312","article-title":"Anaplastic large cell lymphoma (ALCL), ALK-positive","author":"Delsol","year":"2008"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib140","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","first-page":"317","article-title":"Anaplastic large cell lymphoma, ALK-negative","author":"Mason","year":"2008"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib141","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","first-page":"300","article-title":"Primary cutaneous CD30-positive T-cell lymphoproliferative disorders","author":"Ralfkiaer","year":"2008"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib142","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1046\/j.1365-2141.2001.02896.x","article-title":"Anaplastic large cell lymphoma: pathological, molecular and clinical features","volume":"114","author":"Falini","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib143","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1182\/blood.V84.8.2467.2467","article-title":"Clinicopathologic features and treatment outcome of children with large-cell lymphoma and the t(2;5)(p23;q35)","volume":"84","author":"Sandlund","year":"1994","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib144","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib145","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1182\/blood.V73.3.806.806","article-title":"A novel translocation, t(2;5)(p23;q35), in childhood phagocytic large T-cell lymphoma mimicking malignant histiocytosis","volume":"73","author":"Kaneko","year":"1989","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib146","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2141.1989.tb06270.x","article-title":"A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma ('Ki-1 lymphoma')","volume":"71","author":"Rimokh","year":"1989","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib147","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2141.1990.tb02560.x","article-title":"CD30-positive large cell lymphomas ('Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q35","volume":"74","author":"Rimokh","year":"1990","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib148","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib149","first-page":"3509","article-title":"Lymphomas expressing ALK fusion protein(s) other than NPM-ALK","volume":"94","author":"Falini","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib150","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1200\/JCO.2007.11.0700","article-title":"Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster group report","volume":"25","author":"Salzburg","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib151","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1182\/blood.V93.11.3913","article-title":"Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma","volume":"93","author":"Gascoyne","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib152","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1046\/j.1365-2141.2002.03482.x","article-title":"Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group chemotherapy regimens","volume":"117","author":"Williams","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib153","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1182\/blood-2007-07-100958","article-title":"Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study","volume":"111","author":"Le Deley","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib154","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1023\/A:1008352726155","article-title":"Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children\u2014a report from the French Society of Pediatric Oncology","volume":"11","author":"Brugieres","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib155","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1600-0609.2005.00422.x","article-title":"Unrelated bone marrow transplantation for high-risk anaplastic large cell lymphoma in pediatric patients: a single center case series","volume":"75","author":"Cesaro","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib156","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2141.2006.06004.x","article-title":"Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents\u2014a Berlin-Frankfurt-Munster group report","volume":"133","author":"Woessmann","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib157","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Armitage","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib158","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1053\/jd.1999.v40.a95960","article-title":"Primary cutaneous Ki-1(CD30) positive anaplastic large cell lymphoma in childhood","volume":"40","author":"Tomaszewski","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib159","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1200\/JCO.1994.12.5.899","article-title":"Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies","volume":"12","author":"Reiter","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib160","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1182\/blood.V97.12.3699","article-title":"Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster group trial NHL-BFM 90","volume":"97","author":"Seidemann","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib161","first-page":"3591","article-title":"CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology","volume":"92","author":"Brugieres","year":"1998","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib162","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<186::AID-CNCR26>3.0.CO;2-5","article-title":"Large cell non-Hodgkin lymphoma of childhood: analysis of 78 consecutive patients enrolled in 2 consecutive protocols at the Memorial Sloan-Kettering Cancer Center","volume":"88","author":"Mora","year":"2000","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib163","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1002\/cncr.21438","article-title":"Anaplastic large cell lymphoma treated with a leukemia-like therapy: report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol","volume":"104","author":"Rosolen","year":"2005","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib164","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3109\/10428190109064597","article-title":"Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non Hodgkin's lymphoma: a Pediatric Oncology Group study","volume":"42","author":"Laver","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib165","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1200\/JCO.2005.11.075","article-title":"Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial","volume":"23","author":"Laver","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib166","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/pbc.21817","article-title":"Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children's Cancer Group study 5941","volume":"52","author":"Lowe","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib167","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood.V112.11.577.577","article-title":"The impact of the association of vinblastine during induction chemotherapy and as maintenance treatment in children and adolescents with high-risk anaplastic large cell lymphoma: results of a randomized trial of the EICNHL group [abstract]","volume":"112","author":"Le Deley","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib168","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3109\/10428199909145715","article-title":"The therapy of primary adult systemic CD30-positive anaplastic large cell lymphoma: results of 40 cases treated in a single center","volume":"35","author":"Fanin","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib169","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2008.18.1487","article-title":"Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL group","volume":"27","author":"Brugieres","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib170","series-title":"Mature B-cell neoplasms","first-page":"2167","article-title":"Cancer: principles and practice of oncology","author":"Devita","year":"2008"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib171","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting","volume":"7","author":"Lister","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib172","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin's disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib173","doi-asserted-by":"crossref","first-page":"361","DOI":"10.7326\/0003-4819-114-5-361","article-title":"Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease","volume":"114","author":"Henry-Amar","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib174","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","article-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Popperma","year":"2008"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib175","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1038\/sj.leu.2404736","article-title":"Conventional cytogenetics of nodular lymphocyte-predominant Hodgkin's lymphoma","volume":"21","author":"Stamatoullas","year":"2007","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib176","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/13.S1.19","article-title":"Genetic instability in Hodgkin's lymphoma","volume":"13","author":"Re","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib177","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1182\/blood.V99.4.1381","article-title":"Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2","volume":"99","author":"Joos","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib178","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood.V86.4.1464.bloodjournal8641464","article-title":"Numerical chromosome aberrations are present within the CD30+ Hodgkin and Reed-Sternberg cells in 100% of analyzed cases of Hodgkin's disease","volume":"86","author":"Weber-Matthiesen","year":"1995","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib179","first-page":"298","article-title":"Genomic instability and recurrent breakpoints are main cytogenetic findings in Hodgkin's disease","volume":"84","author":"Falzetti","year":"1999","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib180","series-title":"Hodgkin's disease","first-page":"195","article-title":"Cytogenetics of Hodgkin's disease","author":"Sarris","year":"1999"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib181","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/BF00195814","article-title":"Chromosomal in situ hybridization of a Hodgkin's disease-derived cell line (L540) using DNA probes for TCRA, TCRB, MET, and rRNA","volume":"84","author":"Fonatsch","year":"1990","journal-title":"Hum Genet"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib182","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1002\/ijc.21716","article-title":"Molecular biology of Hodgkin's and Reed\/Sternberg cells in Hodgkin's lymphoma","volume":"118","author":"Brauninger","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib183","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1172\/JCI119849","article-title":"Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells","volume":"100","author":"Bargou","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib184","article-title":"Molecular cytogenetic analysis of classical Hodgkin's disease and of Hodgkin cell line [abstract P-062]","volume":"42","author":"Barth","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib185","article-title":"Molecular cytogenetic subtyping of classical Hodgkin's disease [abstract P-063]","volume":"42","author":"Joos","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib186","first-page":"10","article-title":"Systemic molecular cytogenetic study of chromosomal loci encoding member of the REL\/NF-kB and JAK\/STAT pathways in classical Hodgkin lymphoma [abstract]","volume":"73","author":"Maritin-Subero","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib187","first-page":"2220","article-title":"Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin's disease","volume":"92","author":"Carbone","year":"1998","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib188","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood.V97.8.2401","article-title":"Analysis of BCL-6 mutations in classic Hodgkin disease of the B- and T-cell type","volume":"97","author":"Seitz","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib189","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/0140-6736(91)90943-J","article-title":"Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease","volume":"337","author":"Pallesen","year":"1991","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib190","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood.V90.4.1664","article-title":"Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis","volume":"90","author":"Niedobitek","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib191","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/00000478-199405000-00014","article-title":"Nodular lymphocyte predominance Hodgkin's disease","volume":"18","author":"Mason","year":"1994","journal-title":"Am J Surg Pathol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib192","doi-asserted-by":"crossref","first-page":"6131","DOI":"10.1093\/emboj\/16.20.6131","article-title":"Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule","volume":"16","author":"Gires","year":"1997","journal-title":"EMBO J"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib193","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0002-9440(10)64721-9","article-title":"Detection of Epstein-Barr virus in Hodgkin-Reed-Sternberg cells : no evidence for the persistence of integrated viral fragments in latent membrane protein-1 (LMP-1)-negative classical Hodgkin's disease","volume":"156","author":"Staratschek-Jox","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib194","doi-asserted-by":"crossref","first-page":"6216","DOI":"10.1128\/JVI.70.9.6216-6226.1996","article-title":"Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction","volume":"70","author":"Fruehling","year":"1996","journal-title":"J Virol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib195","doi-asserted-by":"crossref","first-page":"7604","DOI":"10.1200\/JCO.2005.02.6310","article-title":"Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study","volume":"23","author":"Keegan","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib196","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.2005.01.701","article-title":"Impact of latent Epstein-Barr virus infection on outcome in children and adolescents with Hodgkin's lymphoma","volume":"23","author":"Claviez","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib197","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1200\/JCO.1987.5.1.27","article-title":"Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy","volume":"5","author":"Santoro","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib198","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1200\/JCO.2003.03.023","volume":"21","author":"Engert","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib199","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2004.12.170","article-title":"ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results","volume":"22","author":"Bonadonna","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib200","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1200\/JCO.2004.01.021","article-title":"Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?","volume":"22","author":"Laskar","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib201","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2005.09.085","article-title":"Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group","volume":"23","author":"Meyer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib202","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1200\/JCO.2006.07.0482","article-title":"Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial","volume":"25","author":"Engert","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib203","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa064601","article-title":"Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease","volume":"357","author":"Ferme","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib204","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.1995.13.5.1080","article-title":"Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report","volume":"13","author":"Bartlett","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib205","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/7.suppl_4.S105","article-title":"Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: an update","volume":"7","author":"Horning","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib206","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO.2000.18.5.972","article-title":"Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492","volume":"18","author":"Horning","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib207","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.20.3.630","article-title":"Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial","volume":"20","author":"Horning","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib208","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood.V77.10.2292.2292","article-title":"Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988","volume":"77","author":"Lohri","year":"1991","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib209","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/sj.bmt.1700963","article-title":"High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"20","author":"Sweetenham","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib210","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib211","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib212","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V97.3.616","article-title":"A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model","volume":"97","author":"Moskowitz","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib213","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/jjco\/hyd036","volume":"30","author":"Takenaka","year":"2000","journal-title":"Jpn J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib214","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/annonc\/mdf221","article-title":"Time-intensified dexamethasone\/cisplatin\/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease","volume":"13","author":"Josting","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib215","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/oxfordjournals.annonc.a059112","article-title":"ChlVPP therapy for Hodgkin's disease: experience of 960 patients","volume":"6","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib216","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1023\/A:1026454831340","article-title":"ESHAP is an active regimen for relapsing Hodgkin's disease","volume":"10","author":"Aparicio","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib217","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","article-title":"Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804","volume":"18","author":"Bartlett","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib218","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3324\/haematol.10661","article-title":"Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma","volume":"92","author":"Santoro","year":"2007","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib219","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1200\/JCO.1995.13.2.396","article-title":"Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation","volume":"13","author":"Colwill","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib220","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/oxfordjournals.annonc.a059242","article-title":"The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease","volume":"6","author":"Ferme","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib221","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF00689103","article-title":"VIM-D salvage chemotherapy in Hodgkin's disease","volume":"27","author":"Phillips","year":"1990","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib222","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1200\/JCO.2005.05.022","article-title":"Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group","volume":"23","author":"Josting","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib223","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/1097-0142(19900315)65:6<1429::AID-CNCR2820650630>3.0.CO;2-B","article-title":"The intergroup Hodgkin's disease in children","volume":"65","author":"Gehan","year":"1990","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib224","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00043426-199124000-00010","article-title":"Comparative effectiveness of two combined modality regimens in the treatment of surgical stage III Hodgkin's disease in children","volume":"13","author":"Sullivan","year":"1991","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib225","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1200\/JCO.1992.10.10.1602","article-title":"Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: the experience of the French Society of Pediatric Oncology","volume":"10","author":"Oberlin","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib226","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1200\/JCO.1997.15.8.2769","article-title":"Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study","volume":"15","author":"Weiner","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib227","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.1998.16.3.897","article-title":"MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial","volume":"16","author":"Hutchinson","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib228","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1200\/JCO.2002.12.007","article-title":"Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy","volume":"20","author":"Nachman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib229","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/13.S1.107","article-title":"Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704","volume":"13","author":"Kelly","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib230","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/00043426-200606000-00008","article-title":"POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with stages I, IIA, IIIA1 Hodgkin disease: a report from the Children's Oncology Group","volume":"28","author":"Kung","year":"2006","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib231","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1200\/JCO.2006.08.4772","article-title":"Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease","volume":"25","author":"Donaldson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib232","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1080\/1042819042000209404","article-title":"Long term outcome in adolescents with Hodgkin's lymphoma: poor results using regimens designed for adults","volume":"45","author":"Yung","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib233","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1200\/JCO.2005.04.5823","article-title":"Hodgkin's lymphoma in adolescents","volume":"24","author":"Foltz","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib234","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1200\/JCO.1993.11.7.1208","article-title":"Cardiac disease following treatment of Hodgkin's disease in children and adolescents","volume":"11","author":"Hancock","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib235","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1200\/JCO.2004.09.109","article-title":"Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy","volume":"22","author":"Adams","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib236","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","author":"Aleman","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib237","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1200\/JCO.1994.12.2.312","article-title":"Second cancer risk following Hodgkin's disease: a 20-year follow-up study","volume":"12","author":"van Leeuwen","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib238","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1182\/blood.V87.9.3625.bloodjournal8793625","article-title":"Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome","volume":"87","author":"Mauch","year":"1996","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2009.07.009_bib239","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1200\/JCO.2000.18.12.2435","article-title":"Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence","volume":"18","author":"Metayer","year":"2000","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775409001444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775409001444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T01:23:56Z","timestamp":1685150636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775409001444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":239,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S0093775409001444"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2009.07.009","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}